Table 3 Relevant features of MuSK MG patients at last follow-up
From: Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes
Characteristic | Males (n = 4) | Females (n = 17) | Total (n = 21) |
|---|---|---|---|
Thymectomy | 0/4 | 0/17 | 0/21 |
Treatment outcome | |||
CSR/PR/MM | 0/0/2 | 1/0/7 | 1/0/9 |
Improved | 0 | 4 | 4 |
Unchanged | 0 | 1 | 1 |
Worse | 0 | 0 | 0 |
Died | 1 | 1 | 2 |
Follow up time in days (SD) | 416.00 ± 113.37 | 1359.40 ± 998.83 | 1202.17 ± 976.73 |
Medications at last follow up | |||
Pyridostigmine bromide | 2/4 | 8/17 | 10/21 |
Corticosteroids | 2/4 | 11/17 | 13/21 |
Tacrolimus | 1/4 | 3/17 | 4/21 |
Azathioprine | 0/4 | 2/17 | 2/21 |